Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.


Journal Article

Regional infusion therapy with melphalan (LPAM) is an accepted treatment for advanced extremity melanoma. However, much room exists for improving the therapeutic index of this type of therapy.Isolated limb infusion (ILI) with temozolomide (TMZ), a novel methylating agent, was performed using a nude rat bearing human melanoma xenograft. Additional rats were treated systemically with TMZ, or regionally with LPAM or 10% dimethyl sulfoxide (DMSO; control) using ILI.Rats that received systemic TMZ showed a poor tumor response and no tumor regression. In contrast, intra-arterial TMZ demonstrated a prolongation of tumor growth delay in a dose-responsive manner. In comparison with LPAM of equitoxic dose, TMZ provided both longer tumor growth delay and a greater number of tumor regressions.These data suggest that ILI with TMZ is an effective treatment for advanced extremity melanoma and may be better than LPAM in this setting.

Full Text

Duke Authors

Cited Authors

  • Ueno, T; Ko, SH; Grubbs, E; Pruitt, SK; Friedman, HS; Tyler, DS

Published Date

  • November 2004

Published In

Volume / Issue

  • 188 / 5

Start / End Page

  • 532 - 537

PubMed ID

  • 15546565

Pubmed Central ID

  • 15546565

Electronic International Standard Serial Number (EISSN)

  • 1879-1883

International Standard Serial Number (ISSN)

  • 0002-9610

Digital Object Identifier (DOI)

  • 10.1016/j.amjsurg.2004.07.014


  • eng